截至10月10日收盘，动物疫苗概念上涨1.93%，位居概念板块涨幅第4，板块内，17股上涨，天康生 物、生物股份、亨通股份等涨幅居前，分别上涨7.52%、4.42%、4.24%。跌幅居前的有申联生物、东方 生物、康华生物等，分别下跌0.67%、0.65%、0.39%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 兵装重组概念 | 4.83 | 国家大基金持股 | -5.04 | | 2025三季报预增 | 3.44 | 同花顺果指数 | -4.64 | | 天津自贸区 | 2.13 | 中国AI 50 | -4.52 | | 动物疫苗 | 1.93 | MCU芯片 | -4.26 | | 草甘膦 | 1.92 | 汽车芯片 | -4.22 | | 深圳国企改革 | 1.85 | AI手机 | -3.99 | | 水泥概念 | 1.84 | AI PC | -3.94 | | 玉米 | 1.71 | 无线耳机 | -3.64 | | 赛马概念 | 1.62 | 存储芯片 | -3.62 | | 猪肉 | 1 ...

8月能繁母猪存栏环比-0.1%，9月猪价新低 猪价自24.1.17低点震荡回升，8月中旬达年内高点21.06元/kg，此后震荡回落;25年9月17日猪价13.71 元/kg，较24年年末下跌16%。9月26日自繁自养、外购仔猪养殖利润-74元/头、-237元/头;行业整体亏损 或可带来产能去化。8月末我国能繁母猪存栏量4038万头，环比-0.1%。关于25年猪价走势，该行认为年 度均价同比下行，差异在于优秀猪企完全成本持续优化，带来养殖利润超预期。此外25年以来猪企产能 变化节奏、行业二育情况、出栏体重等方面或受相关影响而带来超预期变化，值得重点关注。 智通财经APP获悉，中国银河证券发布研报称，持续重点强调关注生猪养殖行业的攻守兼备布局机会， 基于能繁母猪作用值及养殖效率的考虑，25年猪价同比或呈下行走势;综合考虑政策去产能以及行业亏 损去产能，叠加成本下行带来的优秀猪企利润超预期，重点关注成本边际变化显著、资金面良好的优质 猪企。宠物食品行业处成长过程中，优质企业市占率呈提升趋势。该行建议可关注养殖链后周期，推荐 饲料龙头及动物疫苗相关企业。黄鸡价格与猪价有一定相关性，且考虑自身供给端低位，后续价格存上 ...

Core Insights - The animal vaccine sector saw a rise of 1.30%, ranking 9th among concept sectors, with 14 stocks increasing in value, led by TianKang Biological, BioShares, and Jinhe Biological, which rose by 8.20%, 7.17%, and 3.00% respectively [1][2] - The sector experienced a net inflow of 190 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow, led by Hengtong Co. with 71.08 million yuan [2][3] Sector Performance - The animal vaccine sector's performance was highlighted by the following stocks: - Hengtong Co.: 2.41% increase, 4.20% turnover rate, 71.08 million yuan net inflow, 15.05% net inflow ratio - Jinhe Biological: 3.00% increase, 5.44% turnover rate, 30.31 million yuan net inflow, 10.35% net inflow ratio - Kanghua Biological: 2.14% increase, 4.54% turnover rate, 44.90 million yuan net inflow, 10.14% net inflow ratio [3][4] Stock Movements - The top gainers in the animal vaccine sector included: - TianKang Biological: 8.20% increase - BioShares: 7.17% increase - The stocks with the largest declines included: - Shenlian Biological: 1.51% decrease - Dongfang Biological: 1.31% decrease - Xianfeng Holdings: 1.24% decrease [1][4]

Core Viewpoint - The company Zhongmu Co., Ltd. (600195.SH) has stated that it currently does not export any vaccine products to EU countries [1] Company Summary - Zhongmu Co., Ltd. has confirmed through an interactive platform that there are no vaccine exports to the European Union at this time [1]

Meeting Overview - The fifth meeting of the Supervisory Board of the company was held on August 28, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Financial Reporting - The 2025 semi-annual report was approved, confirming that its content and format comply with the regulations of the China Securities Regulatory Commission and the stock exchange, accurately reflecting the company's operational results and financial status [1][2]. - The report disclosed no false records, misleading statements, or significant omissions, and no violations of confidentiality by the personnel involved in its preparation were found [1]. Fund Management - The company confirmed that the use of raised funds complies with relevant regulations, with no changes in the purpose of the funds or harm to shareholder interests [2]. - The profit distribution plan for 2025 was deemed compliant and reasonable, ensuring the company's sustainable development while sharing profits with shareholders [2]. - The Supervisory Board approved the temporary use of up to 210 million yuan of idle raised funds for cash management, ensuring it would not affect normal business operations [3]. - Additionally, the company approved the use of 250 million yuan of idle self-owned funds for cash management under necessary approval procedures [3]. Related Transactions - The wholly-owned subsidiary, Luoyang Lepet Health Technology Co., Ltd., plans to acquire four "Meng Tuan" trademarks from Century Mengbang (Shanghai) Information Technology Co., Ltd. for 10,000 yuan, which aligns with the company's pet business development strategy and enhances brand competitiveness [4].

Core Insights - Yongshun Biological (stock code: 839729) reported a revenue of 122 million yuan for the first half of 2025, representing a year-on-year increase of 2.14% [1] - The net profit attributable to shareholders reached 19.72 million yuan, up 26.95% year-on-year, with a 50.72% increase when excluding the impact of share-based payments, indicating strong growth momentum [1] Business Performance - The core business of pig vaccines showed a significant recovery, with sales of live pig vaccines increasing by 13.95% year-on-year, driven by rising pig prices and increased enthusiasm among small and medium-sized farmers [1] - The revenue from the pig circovirus vaccine increased by 2.84 million yuan, becoming a new growth point for performance [1] Research and Development - The company increased its R&D investment to 10.25 million yuan, accounting for 8.42% of revenue, and successfully obtained new veterinary drug certificates and production licenses for several projects [1] - The company received clinical approval and invention patent authorization for multiple projects, laying a solid foundation for future development [1] Cost Management - Through continuous optimization of production processes, the unit costs of the main products, including the pig pseudorabies and avian influenza vaccines, decreased by approximately 11% and 9% respectively, significantly enhancing product competitiveness [1] - The company improved operational efficiency through supply chain optimization and refined management [1] Marketing Strategy - The company adheres to a "channel sinking, marketing terminal" strategy, resulting in a 22.60% year-on-year increase in domestic distributor revenue [2] - Significant success in overseas market expansion, particularly in Vietnam and Egypt, where revenue reached 13.03 million yuan, a substantial year-on-year growth of 88.61% [2] Future Outlook - Yongshun Biological will continue to pursue an innovation-driven development strategy, focusing on market demand, optimizing product structure, and enhancing product quality and service levels to consolidate and expand market advantages [2]

Group 1 - The report emphasizes the importance of focusing on the pig farming industry, highlighting opportunities for both offensive and defensive strategies. It suggests that pig prices may trend downward year-on-year by 2025, while remaining relatively stable within the year, alongside a decrease in costs leading to profits exceeding expectations. The focus should be on high-quality pig companies with significant changes in marginal costs and good financial conditions [1] - The pet food industry is in a growth phase, with leading companies increasing their market share [1] - Attention is recommended for the post-cycle of the breeding chain, specifically suggesting the feed leader Haida Group and companies related to animal vaccines [1] - There is a correlation between yellow chicken prices and pig prices, with the potential for price increases in the future due to low supply levels [1]

Core Viewpoint - The report provides a detailed account of Wuhan Keqian Biological Co., Ltd.'s fundraising activities, including the total amount raised, usage of funds, and management practices, ensuring compliance with regulatory requirements [1][2][3][4][5] Fundraising Overview - The company raised a total of RMB 1,227.45 million through the issuance of 105 million shares at a price of RMB 11.69 per share, with net proceeds amounting to RMB 1,158.26 million after deducting underwriting fees [1] - As of December 31, 2024, the cumulative amount invested from the raised funds was RMB 854.01 million, leaving a balance of RMB 337.87 million [1][2] Fund Usage and Management - The company has established a dedicated account for managing the raised funds, adhering to the "Three-party Supervision Agreement" with the bank and sponsor to ensure proper usage [1][2] - As of June 30, 2025, the company had directly invested RMB 89.23 million into fundraising projects and incurred a total of RMB 5.20 million in handling fees [2][3] Cash Management - The company has utilized idle funds for cash management, achieving a total return of RMB 13.42 million from interest and investment income [1][3][5] - The total amount of idle funds managed was RMB 365 million, with a cash management balance of RMB 230 million as of June 30, 2025 [5] Project Changes - The company terminated the "Animal Biological Product Workshop Technical Renovation Project" and redirected the remaining funds of RMB 287.14 million to the "High-level Animal Vaccine Industrialization Base Construction Project (Phase I)" [4][5] - The decision to change the project was approved by the board and the supervisory committee, ensuring compliance with regulatory requirements [4][5] Fund Usage Reporting - The report includes detailed tables showing the usage of raised funds, with a total of RMB 94.32 million invested in various projects by the end of the reporting period [4][5] - The company has not encountered any issues in disclosing the usage of funds, maintaining transparency in accordance with regulatory guidelines [4]

Core Viewpoint - Reap Bio (300119.SZ) reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company achieved an operating revenue of 1.708 billion yuan, representing a year-on-year growth of 20.53% [1] - The net profit attributable to shareholders was 257 million yuan, showing a substantial year-on-year increase of 57.59% [1] Dividend Policy - The company announced that it will not distribute cash dividends, issue bonus shares, or increase capital from reserves [1]

Core Insights - The company reported a revenue of 487 million yuan for the first half of 2025, representing a year-on-year growth of 21.67% [1] - The net profit attributable to shareholders reached 220 million yuan, showing a year-on-year increase of 44.09% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 190 million yuan, reflecting a year-on-year growth of 43.12% [1] - The basic earnings per share stood at 0.47 yuan, indicating strong financial performance [1] - The increase in revenue is attributed to improved market conditions and rising sales volume [1]